People who exhibit high physical activity sometimes use products with anesthetic, anti-inflammatory, warming properties in order to be in shape and maintain the functional capabilities of the musculoskeletal system. No exception and such a complex, subtle, susceptible to many influences from the outside psycho-physiological function, as male sexuality. It is believed that natural sexual activity should be spontaneous, unconstrained and not cause physical or psychological discomfort.
All this is largely indirectly erectile function, the quality of which men determine, depending on these parameters:
- the ability to achieve an erection;
- sufficient severity;
- the ability to maintain an erection as long as necessary to complete intercourse.
Often it is enough just a small push to maintain the physiological mechanism of erection, return it to the natural characteristics. A big step forward, almost a sexual revolution, was the emergence 10 years ago in the world’s leading pharmaceutical markets, sildenafil, the first inhibitor of phosphodiethyl esterase type 5 (PDE-5). A few years later, two more drugs of this class were brought to the market. The newest PDE-5 inhibitor that received marketing authorization in the EU is Levitra (Vardenafil).
In what direction is the evolution of drugs of this class? Development companies on their corporate sites and in the media answer this question in the following way: we strive mainly to increase the security and naturalness of the effect achieved. Indeed, men who use the drug do not want to feel as if they had bought a train or plane ticket and must follow the schedule. Agree, quite inconvenient, going to take the drug, refrain from eating food, and then wait a certain time before the start of its action, or take a pill after a meal, and then wait another hour. Men do not want sexuality intimacy to be violated; they also do not want to experience limitations that are associated with illness and weakness.
Rapid onset of action, pronounced activity, high selectivity and lack of interaction with moderate-fat foods are the parameters by which Levitra has excellent characteristics. It is probably due to this that the majority of patients prefer Levitra over Sildenafil because they are more satisfied with the results of the treatment, as evidenced by data from the new comparative study CONFIRMED with 1057 men.
Vardenafil is the most potent PDE-5 inhibitor, excelling in terms of this indicator sildenafil and tadalafil. At the same time, Vardenafil minimally inhibits other types of this enzyme. To inhibit the activity of PDE-6 (contained in the retina and responsible for vision) by 50% with the same degree of inhibition of PDE-5, the concentration of Vardenafil should be more than 2 times higher than Sildenafil. This high selectivity provides a favorable safety profile of the drug.
Acceptance of alcohol (0.5 g/kg body weight, that is, about 40 ml of absolute alcohol by a person with a body weight of 70 kg) does not affect the concentration of Vardenafil in the blood plasma. The effectiveness of Levitra is also not affected by the consumption of food of moderate fat content, in connection with which the patient is spared from the need to coordinate the diet and the time of taking the drug. Levitra does not affect semen performance, the level of sex hormones in serum, does not impair the functional abilities of patients with ischemic heart disease to perform the treadmill test, and even by 15% reduces the duration of the period to decrease ST segment by 1 mm in those was initially reduced by 1 mm or more.
The results of clinical trials proved the effectiveness of the drug in patients with erectile dysfunction of different etiology (organic, psychogenic, mixed), the severity and duration of the disease. There was a tendency to higher efficacy compared with placebo with a greater degree of severity and duration of the disease.
Thus, according to the clinical trial results described in the instructions for medical use, in men with erectile dysfunction, Levitra significantly increases the frequency of achieving an erection sufficient for penetration (SEP2) and successful completion of sexual intercourse.
Bayer continues its research activity related to the Levitra drug, and most recently, on March 26, at the European Association of Urology Congress, the results of a new study were presented, according to which the drug is effective and has a favorable safety profile in patients with dyslipidemia. A double-blind trial was conducted with about 400 men taking statins.
Thus, Levitra – a new, highly selective drug with a favorable safety profile – can be successfully used in men with erectile dysfunction of varying severity and etiology. Due to the pronounced and rapid onset effect with good endurance, Levitra allows you to regain the joy of natural sexual relationships.